Everen Declares $350 Million Dividend
27.3.2025 17:30:00 EET | Business Wire | Press release
Everen Limited today announced a dividend of $350 million, affirming Everen’s commitment to delivering value to its shareholders.
The decision by Everen’s Board of Directors was announced at the Company’s Annual General Meeting (AGM) in Bermuda on Thursday, March 20, 2025. The dividend is payable on or before September 30, 2025 to shareholders of record on March 20, 2025.
Robert Foskey, President & CEO of the Everen Group, commented: “Everen continues to go from strength to strength with an exceptional year in 2024, both from a financial and operational point of view. We closed out the year with some of our best-ever results, driven by strong investment performance and modest incurred losses.”
Addressing Everen’s shareholders, Mr. Foskey said: “For the twelfth year in a row, we are pleased to once again declare a substantial dividend. Cumulatively, over the past 12 years, we have returned over $3.8 billion in dividends to our shareholders. Everen’s consistent financial returns, coupled with our disciplined approach to capital management, puts us in a solid position to return value to our shareholders year after year.”
Mr. Foskey also noted that the Company closed out the year with the highest number of members since 2005, with five new members joining in 2024, bringing total membership to 72 members worldwide.
At the meeting, shareholders elected Everen’s Board of Directors who will serve until the March 2026 AGM. Mr. John Weisner was elected as Chair and Mr. Brian Mullen was elected Vice Chair.
The AGM followed a two-day Shareholder Conference, March 18-19, at the Hamilton Princess in Bermuda. The Everen Group’s flagship conference is Bermuda’s largest energy insurance event with more than 90 energy company representatives attending from the Americas, Europe and as far afield as Australia, New Zealand and Japan. Experts in energy, earth systems science, climate change litigation and risk management spoke on the latest trends and emerging issues in the energy sector, including carbon capture, energy transition and climate attribution.
About Everen Group
The Everen Group – a group of leading energy insurance companies based in Bermuda – includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third-party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry-owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also has a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.
For further information about the Everen Group, please visit www.everengroup.bm
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327830406/en/
Contacts
For inquiries regarding this press release, please contact:
Elizabeth Deacon, Communications Manager on elizabeth.deacon@everengroup.bm
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom